Chronic daily administration of oral etoposide in refractory lymphoma |
| |
| Affiliation: | 1. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research, 10115, Berlin, Germany;2. DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany;1. Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1714614411, Iran;2. Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;3. Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran;1. Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany;2. German Cancer Consortium (DKTK), Heidelberg, Germany;3. Department for Bone Marrow Transplantation, West-German Cancer Center, University Hospital Essen, Essen, Germany;1. Biomedical Research Foundation, House # 7, Apartment # 1A, Road # 1/B, Chairman Bari, Banani, Dhaka 1213, Bangladesh;2. Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh;3. School of Environmental Science and Management, Independent University, Bangladesh |
| |
| Abstract: | ![]()
In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28–35 days, depending on myelosuppression. 15 patients (60%) had partial responses (95% CI 41–77%), while 10 patients had no response. Median time to disease progression was 5 months (range 2–13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28%) had a leucocyte nadir below 1000/μl during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
